Sputnik V Trial India
- All
- News
- Videos
-
Dr Reddy's Hopes To Submit Sputnik V Light Trial Data To Drug Regulator In November
Dr Reddy's Laboratories Ltd is expected to submit Phase 3 trials data of single-dose Russian COVID-19 vaccine Sputnik Light to the Indian drug regulator next month, even as the city-based firm is getting ready to conduct trials of the jab in 2 to 18
-
"Trial Data Clear, Transparent...": Russian Scientists Defend Sputnik V
Russian scientists leading clinical studies for the Sputnik V COVID-19 vaccine have responded to claims of "serious concerns over interim results from phase 3 trials" by stressing their data meets "clear and transparent standards..."
-
Sputnik Vaccine For India? Regulator Seeks More Data: Report
An expert panel of India's drug regulator on Friday sought additional data from drugmaker Dr.Reddy's Laboratories on its Sputnik V COVID-19 vaccine trial, in its second such request after an initial evaluation in February.
-
Sputnik 5, Efficacy 91.6%, For India? Meeting Today To Review
The Subject Expert Committee (SEC) of the Indian drug regulator will meet today to take up an application by pharma giant Dr Reddy's Laboratories seeking emergency approval for Sputnik V, the Russia-developed coronavirus vaccine. The vaccine has an efficacy of 91.6 per cent.
-
Dr Reddy's Aims To Launch Russia's Sputnik V Vaccine For Emergency Use In March
Dr Reddy's Laboratories, which is conducting Phase 3 trials of Russia's COVID-19 vaccine Sputnik V, believes the jab is expected to be launched in India through Emergency Use Authorisation, a senior official of the city-based drug maker said on Friday.
-
Russian Covid Vaccine In Phase 3 Trial, To Cost Less Than $10 Per Dose In India
The Russian COVID-19 vaccine "Sputnik V" will cost less than USD 10 (about Rs 730) per shot in India and the price is the same for all countries, Kirill Dmitriev, CEO of Russian Direct Investment Fund (RDIF) said on Thursday.
-
Sputnik V COVID-19 Vaccine Safe In India Mid-Stage Trial: Dr Reddy's
Dr Reddy's Laboratories Ltd said on Monday an independent board found Russia's Sputnik V COVID-19 vaccine to be safe in its mid-stage trial in India, and recommended progressing to late-stage trials.
-
17 Volunteers Given Sputnik V Vaccine During Clinical Trial In Pune
A total of 17 volunteers have been administered Russia's Sputnik V coronavirus vaccine at a Pune hospital as part of the human clinical trials, doctors said today.
-
Dr Reddy's, Russian Firm RDIF Begin Clinical Trials For Covid Vaccine Sputnik V In India
Dr Reddy's Laboratories and the Russian Direct Investment Fund (RDIF) on Tuesday announced the start of adaptive phase 2/3 clinical trials for COVID-19 vaccine Sputnik V in India after receiving necessary clearance from the Central Drugs Laboratory in Himachal Pradesh.
-
Bengal Likely To Lose Chance To Conduct Sputnik V Vaccine Phase II Trial
West Bengal will lose the chance to conduct Phase II clinical trial of Russian COVID-19 vaccine candidate Sputnik V because of the delay in grant of approval by the state government, a top official of an organisation involved in facilitating the exercise said on Sunday.
-
Dr Reddy's Hopes To Submit Sputnik V Light Trial Data To Drug Regulator In November
Dr Reddy's Laboratories Ltd is expected to submit Phase 3 trials data of single-dose Russian COVID-19 vaccine Sputnik Light to the Indian drug regulator next month, even as the city-based firm is getting ready to conduct trials of the jab in 2 to 18
-
"Trial Data Clear, Transparent...": Russian Scientists Defend Sputnik V
Russian scientists leading clinical studies for the Sputnik V COVID-19 vaccine have responded to claims of "serious concerns over interim results from phase 3 trials" by stressing their data meets "clear and transparent standards..."
-
Sputnik Vaccine For India? Regulator Seeks More Data: Report
An expert panel of India's drug regulator on Friday sought additional data from drugmaker Dr.Reddy's Laboratories on its Sputnik V COVID-19 vaccine trial, in its second such request after an initial evaluation in February.
-
Sputnik 5, Efficacy 91.6%, For India? Meeting Today To Review
The Subject Expert Committee (SEC) of the Indian drug regulator will meet today to take up an application by pharma giant Dr Reddy's Laboratories seeking emergency approval for Sputnik V, the Russia-developed coronavirus vaccine. The vaccine has an efficacy of 91.6 per cent.
-
Dr Reddy's Aims To Launch Russia's Sputnik V Vaccine For Emergency Use In March
Dr Reddy's Laboratories, which is conducting Phase 3 trials of Russia's COVID-19 vaccine Sputnik V, believes the jab is expected to be launched in India through Emergency Use Authorisation, a senior official of the city-based drug maker said on Friday.
-
Russian Covid Vaccine In Phase 3 Trial, To Cost Less Than $10 Per Dose In India
The Russian COVID-19 vaccine "Sputnik V" will cost less than USD 10 (about Rs 730) per shot in India and the price is the same for all countries, Kirill Dmitriev, CEO of Russian Direct Investment Fund (RDIF) said on Thursday.
-
Sputnik V COVID-19 Vaccine Safe In India Mid-Stage Trial: Dr Reddy's
Dr Reddy's Laboratories Ltd said on Monday an independent board found Russia's Sputnik V COVID-19 vaccine to be safe in its mid-stage trial in India, and recommended progressing to late-stage trials.
-
17 Volunteers Given Sputnik V Vaccine During Clinical Trial In Pune
A total of 17 volunteers have been administered Russia's Sputnik V coronavirus vaccine at a Pune hospital as part of the human clinical trials, doctors said today.
-
Dr Reddy's, Russian Firm RDIF Begin Clinical Trials For Covid Vaccine Sputnik V In India
Dr Reddy's Laboratories and the Russian Direct Investment Fund (RDIF) on Tuesday announced the start of adaptive phase 2/3 clinical trials for COVID-19 vaccine Sputnik V in India after receiving necessary clearance from the Central Drugs Laboratory in Himachal Pradesh.
-
Bengal Likely To Lose Chance To Conduct Sputnik V Vaccine Phase II Trial
West Bengal will lose the chance to conduct Phase II clinical trial of Russian COVID-19 vaccine candidate Sputnik V because of the delay in grant of approval by the state government, a top official of an organisation involved in facilitating the exercise said on Sunday.
